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Inward- and outward-facing X-ray crystal
structures of homodimeric P-glycoprotein
CmABCB1
Atsushi Kodan1, Tomohiro Yamaguchi2, Toru Nakatsu2,3, Keita Matsuoka2, Yasuhisa Kimura1,
Kazumitsu Ueda1,4 & Hiroaki Kato 2,3
P-glycoprotein extrudes a large variety of xenobiotics from the cell, thereby protecting tissues
from their toxic effects. The machinery underlying unidirectional multidrug pumping remains
unknown, largely due to the lack of high-resolution structural information regarding the
alternate conformational states of the molecule. Here we report a pair of structures of
homodimeric P-glycoprotein: an outward-facing conformational state with bound nucleotide
and an inward-facing apo state, at resolutions of 1.9 Å and 3.0 Å, respectively. Features that
can be clearly visualized at this high resolution include ATP binding with octahedral coor-
dination of Mg2+; an inner chamber that signiﬁcantly changes in volume with the aid of tight
connections among transmembrane helices (TM) 1, 3, and 6; a glutamate−arginine inter-
action that stabilizes the outward-facing conformation; and extensive interactions between
TM1 and TM3, a property that distinguishes multidrug transporters from ﬂoppases. These
structural elements are proposed to participate in the mechanism of the transporter.
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P-glycoprotein (P-gp; also known as ABCB1 or MDR1), amember of the ATP-binding cassette (ABC) transporterfamily, is a primary transporter that mediates active efﬂux
of various hydrophobic chemicals from the cell1–3. Its substrates
include more than a hundred chemically diverse molecules,
including therapeutic drugs, steroid hormones, and signaling
molecules4. P-gp plays important roles in normal physiology and
is an essential component of many physiological barriers5. The
protein consists of a minimum of four core domains: two
transmembrane domains (TMDs), which create the translocation
pathway for substrates, and two nucleotide-binding domains
(NBDs), which bind and hydrolyze ATP to power the transport
process6. These four domains can exist either as two separate
polypeptides or fused together in a single long polypeptide with
an internal duplication. Although several crystal structures of
eukaryotic P-gp proteins have been determined in an inward-
facing conformation7–10, no outward-facing X-ray crystal struc-
ture was previously available, except for bacterial homologs11,12,
probably because the outward-facing state of P-gp in complex
with a nucleotide is not stable enough to be crystallized13. The
inward-facing structures reveal a large, kernel-shaped inner
chamber in the center of TMDs, extending from the middle of the
bilayer membrane to the cytosol9. This chamber is surrounded by
all 12 TM helices and has two gates: one open to the membrane,
and the other, located at the bottom center region of the TMDs,
open to the cytosol9. At the apex of the chamber is a cluster of
amino acids residues with aromatic hydrophobic side-chains,
which are involved in substrate and inhibitor binding7. Recently,
the overall conformational movement of mouse P-gp was deter-
mined by double electron−electron resonance14. However, the
change in the structure of the inner chamber during substrate
transport remained to be elucidated.
A recent study reported the cryo-EM structure of human P-gp
in an outward-facing conformation15. The structure has only a
small opening on the extracellular side of the membrane, and the
TM helices are packed closely in the membrane inner leaﬂet. On
the other hand, the outward-facing crystal structure of the bac-
terial homolog MsbA has wide gaps open to the outer leaﬂet
region of the membrane; its large inner chamber, which reaches
the intracellular region beyond the cell membrane, is exposed to
the extracellular space and accessible from the outer leaﬂet11,12.
The considerable difference between these structures may reﬂect
differences in their functions (multidrug exporter vs. lipid ﬂop-
pase) or more general differences between eukaryotic and pro-
karyotic ABC proteins. Due to the low resolution of the cryo-EM
structure, however, it is difﬁcult to investigate the detailed
structural features, especially side-chain positions and the struc-
tural changes they undergo during the transport process via
alternating conformational conﬁgurations16.
Here we present a pair of crystal structures of dimeric P-gp
from Cyanidioschyzon merolae, a transporter with quite similar
functional properties to human P-gp9: an outward-facing
nucleotide bound state (1.9 Å resolution) and an inward-facing
apo state (3.0 Å). We solved these structures by generating a
mutant in which the outward-facing state was sufﬁciently stable
for crystallization; the same mutant was used to obtain both of the
crystal structures. The resultant high-resolution crystallographic
data are reliable enough to allow a discussion of structure and
mechanism at the level of individual amino acid residues. Cru-
cially, the conformational change from inward- to outward-facing
is accompanied by shrinkage of the large inner chamber from the
cytosolic side due to tilting and rotation of the TMDs. This
contraction of the chamber could extrude a variety of substrates
toward the extracellular side. The TMD motion is caused by NBD
dimerization upon binding to Mg2+ and ATP. NBD dimerization
triggers a series of local conformational changes such as
movement of the Q-loop, intracellular helices IH1 and IH2, and
TM helices via a relay of van der Waals interactions within the
α3-Q-loop and coupling helices. Structural comparison of the two
states suggests a free energy transduction process whereby the
energy derived from ATP binding is stored in the structural strain
of the TMDs.
Results
Structure determination. To obtain the outward-facing con-
formation of CmABCB1 in a crystalline state, we introduced
mutations that shifted the conformational equilibrium toward the
outward-facing state in complex with Mg2+ and nucleotide.
Previously, we reported that the hydrogen bonds formed between
TM1 and TM6 near the top of the inward-facing structure
(Supplementary Fig. 1a) stabilize the inward-facing conformation
in wild-type CmABCB19. Accordingly, we generated a mutant in
which these hydrogen bonds are disrupted by the Q147ATM1/
T381ATM6 double mutation (hereafter termed the QTA mutant).
These mutations had a slight effect on protein function, as
determined by drug resistance (Supplementary Fig. 1b) and ATP
hydrolysis activity (Supplementary Fig. 1c–g, Supplementary
Table 1). We successfully determined the outward-facing struc-
ture of the QTA mutant bound to the nonhydrolyzable ATP
analog adenylyl imidodiphosphate (AMP-PNP) and Mg2+ at a
1.9 Å resolution (Fig. 1c, d, g, h and Table 1). The extracellular
hydrophilic region of the TMDs exhibited ambiguous electron
density, suggesting that the upper parts of the TM helices and
extracellular loops in this region are highly mobile. The inward-
facing apo structure of the mutant, determined at a 3.0 Å reso-
lution (Fig. 1a, b, e, f and Table 1), was almost identical to that of
the WT9, with a root-mean-squared deviation (r.m.s.d.) value of
0.47 Å for all Cα atoms. In the region containing the mutated
Gln147TM1 and Thr381TM6 residues, the two structures are
almost superimposable (Supplementary Fig. 1h).
Comparison of the inward- and outward-facing conformations
of QTA CmABCB1 revealed that the overall conformational
changes between both states is achieved by 9.5° tilting and 21°
rigid-body rotation of the subunits (Supplementary Movie 1, 2).
The helical interactions of TM6−TM4 and TM6−TM5 in the
outward-facing structure are formed by a conformational change
from the inward-facing structure (Fig. 1a, c), whereas the TM1
−TM6 interaction is dissociated (Fig. 1e, g). Interestingly, TM4 is
partly unwound in the inward-facing conformation, but adopts a
more regular alpha-helical geometry in the outward-facing
conformation (Fig. 1e, g). Because of the conformational change,
the large inner chamber with the ceiling in the inward-facing
structure is signiﬁcantly reduced in volume and open to the
extracellular space in the outward-facing structure (Fig. 1b, d, f,
h), suggesting that the large space in the inner chamber of the
inward-facing structure varies due to conformational changes of
the TMDs, like an elastically contractile machine. The QTA
CmABCB1 structure in the outward-facing state is similar to that
of human P-gp15 but quite different from those of the bacterial
homologs Sav186611 and MsbA12 (Supplementary Fig. 2a). Each
bacterial homolog still has a large inner space in the outward-
facing conformation. In regard to the conformational change of
mammalian P-gp, comparison among many inward-facing mouse
P-gp structures revealed a tilting and rotation induced by NBD
movement10, similar to (or a component of) the conformational
change in CmABCB1.
Structural changes of the interior of the TMDs. Interior views
of the structures reveal local conformational changes combined
with tilting and twisting of the TM helices (Fig. 2, Supplementary
Movie 1), while lateral views of both dimer structures reveal
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structural changes forming a substrate pathway from the interior
side to the extracellular side. The TM1–TM6 (TM1*–TM6*)
intra-subunit interactions mediated by Phe384TM6, Phe138TM1,
and Phe142TM1, which close the outlet pathway formed in the
center of the bundle, are dissociated in the outward-facing
structure by horizontal rotation of the side-chain of Phe384TM6
accompanied by twisting of TM6 or TM6* (Fig. 2), which could
be induced by tilting of TM5 or TM5*. Concomitantly, the inter-
subunit TM6−TM1* or TM6*−TM1 interactions form via the
same side chains (Fig. 2, upper panels). Tyr358 in TM5 is also
involved in extracellular gating. In the ﬁgures, secondary struc-
ture elements and amino acid residues belonging to the other
subunit are indicated by asterisks.
Comparison of the inside view of the structures in Fig. 3 reveals
that close inter-subunit contacts via each pair of side chains
(Gln229TM3, Tyr233TM3, and Lys237TM3 in TM3−TM3* (Fig. 3b)
and Ala240TM3−Gln398*TM6 in TM3−TM6* or Ala240*TM3
−Gln398TM6 in TM3*−TM6 (Fig. 3d)) are formed on the
cytosolic side in the outward-facing structure, leading to the
largest change in chamber volume. Because these residues seem to
regulate the chamber space, we refer to them collectively as the
chamber contraction regulator. The van der Waals contacts of
Gln398TM6−Ala240*TM3 are assisted by those of Gln398TM6
−Phe347TM5 and hydrogen bonds between Gln398TM6
−Arg181*TM2 and Arg181*TM2−Glu131*TM1 (Fig. 3d, Supple-
mentary Fig. 2b). Mutagenesis of Tyr233TM3, Lys237TM3,
A240TM3, or Gln398TM6 signiﬁcantly decreased transport activity
(Fig. 3e), indicating that those residues participate in the
transport function.
The chamber contraction regulator, especially the van der
Waals contacts of Gln398TM6−Ala240*TM3, appears to cause a
structural change with spring-like movement of the partially
unfolded TM helices, typically TM6 (Fig. 3c, d). In the outward-
facing structure, TM6 is deformed and unwound at Gly389TM6,
Gly392TM6, and Gly394TM6. We propose that this deformation, a































Fig. 1 Apo inward-facing and Mg2+•AMP-PNP-bound outward-facing structures of QTA CmABCB1. Anterior (a–d) and lateral (e, f) views of the QTA
CmABCB1 structures in the inward- (a, b, e, f) and outward-facing (c, d, g, h) conformations are shown as cartoon representations (a, c, e, g) or as a
cutaway surface representations of the TMDs with the interior shown in black (b, d, f, h). One subunit is colored, and the other is shown in gray. Secondary
structure elements and amino acid residues belonging to the other subunit are indicated by asterisks in all ﬁgures. Horizontal black and gray bars represent
the expected positions of the hydrophilic and hydrophobic surfaces of the lipid membrane, respectively. In b, f, d, h, the cross-section passes through a
crystallographic twofold axis. NBDs are shown as outlines for simplicity. In c, d, g, h, bound Mg2+•AMP-PNP molecules at NBDs are shown as spheres
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the inward-facing structure. Several conserved Gly residues in
TM6 and TM12 of human P-gp have been proposed to cause
helical movement, thereby contributing to transport function17
and structural ﬂexibility18.
TM joints differentiate P-gps from bacterial homologs. The
spatial helical arrangements of the TMDs and the inner chamber
shapes of outward-facing conformations differ substantially
between CmABCB1 and the bacterial homologs Sav186611 and
MsbA12 (Fig. 4 and Supplementary Fig. 2). CmABCB1 has
characteristic inter-helical interactions called a “TM1−3 joint”, in
which TM1 forms close contacts (~4.0 Å) with TM3 via
Gly132TM1−Ala246TM3 and Ser128TM1−Gly239TM3, and a
“TM3−6 joint”, in which TM3 interacts with TM6 (~4.0 Å dis-
tance) via Gly251TM3 sandwiched by Ala386TM6 and Gly389TM6.
These small side-chain residues provide tight and restricted
contacts between those helices that are maintained in both
inward- and outward-facing conformations and function as hinge
joints during conformational changes (Fig. 4a). The tight joints
among TM1−TM3−TM6 maintain the close inter-subunit dis-
tance (9.0 Å) between TM3−TM6* or TM3*−TM6 in the
outward-facing state; consequently, inter-subunit van der Waals
contacts are formed between Ala240TM3 and Gln398*TM6 or
Ala240*TM3 and Gln398TM6 (Fig. 4c). The human P-gp struc-
ture15 also exhibits close contact between TM1, TM3, and TM6
(Fig. 4d). By contrast, the Sav1866 and MsbA structures have
neither TM joints nor close contacts between TM1, TM3, and
TM6 at the positions corresponding to the TM joints, and TM1
and TM3 are distant from each other (Fig. 4b, e and Supple-
mentary Fig. 2b). Thus, the equivalent inter-subunit distance
between TM3–TM6* or TM3*–TM6 is greater than the side-
chain interaction distance (17 Å) between Asn141TM3 and
Ala299*TM6 or Asn141*TM3 and Ala299TM6, corresponding to
Ala240TM3 and Gln398*TM6 or Ala240*TM3 and Gln398TM6 in
Sav1866 (Fig. 4e).
The residues involved in TM joints are conserved in eukaryotic
P-gps but not in Sav1866 or MsbA (Fig. 4f and Supplementary
Fig. 3). When we introduced mutations at key residues of the
TM1−3 joint, Gly132TM1 and Ala246TM3, the drug resistance
IC50 of all the mutants drastically decreased (Fig. 4g). Gly191TM3
and Gly341TM6 of human P-gp, corresponding respectively to
Gly239TM3 and Gly389TM6 of CmABCB1, are important for
transport functions19,20. Accordingly, we propose that these TM
joints play crucial roles in structural change of the chamber in the
substrate transport cycle of P-gp, suggesting an intrinsic
mechanistic difference between multidrug transporters and
ﬂoppases.
Conformational change induced upon Mg2+-nucleotide bind-
ing. A comparison of outward- and inward-facing states revealed
Table 1 Data collection and reﬁnement statistics
QTA outward Hg derivative (QTA outward) QTA inward
Data collection
Space group P4132 P4132 R32
Cell dimensions
a, b, c (Å) 174.3, 174.3, 174.3 176.0, 176.0, 176.0 179.7, 179.7, 157.7
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 120
Wavelength 1.0000 1.00789 1.0000
Resolution (Å) 43.6−1.89 (2.00−1.89)a 50−2.70 (2.75−2.70)a 47.1−3.02 (3.20−3.02)a
Rsym 0.152 (1.187) 0.148 (0.382) 0.102 (0.629)
Total reﬂections 1,517,693 1,074,412 192,073
Unique reﬂections 72,007 49,994 19,238
I /σI 13.0 (1.9) 51.6 (13.1) 14.3 (2.4)
Completeness (%) 99.2 (95.4) 100.0 (100.0) 99.6 (98.5)
Redundancy 21.1 (18.2) 21.5 (19.7) 9.98 (10.1)
CC1/2 (%) 99.8 (74.0) (98.3)b 99.9 (91.8)
Processing programs XDS (ver. Jan. 26, 2018) HKL2000 (ver. 0.98) XDS (ver. Nov. 3, 2014)
Reﬁnement
Resolution (Å) 43.6−1.90 (1.95−1.90) 47.1−3.02 (3.10−3.02)
No. reﬂections 67,507 18,276














Bond lengths (Å) 0.011 0.010
Bond angles (°) 1.537 1.490
The number of crystals for each structure is one
aValues in parentheses are for highest-resolution shell
bThe overall CC1/2 value of the Hg derivative has not been calculated by HKL2000
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characteristic conformational differences in the NBD and
its interface with the TMD, induced by NBD dimerization upon
Mg2+-nucleotide binding (Supplementary Fig. 4a), which had not
been previously reported for B-subfamily ABC proteins. These
differences are distributed from the Mg2+-nucleotide site in the
RecA-like subdomain of the NBD, through the Q-loop and
connecting α3 helix in the helical subdomain, up to IH1 and IH2
of the TMD (Fig. 5a and Supplementary Movie 2). Mg2+ is bound
in optimal octahedral coordination with 2.0−2.1 Å bonds formed
by two oxygens from the β- and γ-phosphates of AMP-PNP, the
hydroxyl group of Ser485P-loop, the side-chain carbonyl group of
Gln529Q-loop, and two oxygens of water molecules (Fig. 5b and
Supplementary Fig. 4c). By contrast, when the NBDs of ABCB2
were crystallized without TMDs21, the Mg2+ coordination posi-
tion for Gln529Q-loop in CmABCB1 was occupied by a water
molecule (Supplementary Fig. 4d), suggesting that the association
with the TMD may restrict the movement of the NBD. Because
the Q-loop and α3 interact tightly with IH2* via the van der
Waals contacts between [Val532Q-loop, Phe534Q-loop, Tyr544α3]
and [Thr311*IH2, Phe315*IH2], and IH2* interacts with IH1 via
Ile309*IH2 and Phe212IH1 in both the inward- and outward-
facing conformational states, Mg2+ and Q-loop coordination is
likely to trigger the movement of the TMDs through a relay of
conformational changes of the Q-loop, α3 helix, IH2*, and IH1
during NBD dimerization (Fig. 5c; Supplementary Movie 2).
Furthermore, the adenine moiety of bound AMP-PNP supports
the interaction with IH2* and IH1 through hydrogen-bond net-
works (Supplementary Fig. 4b). Consequently, the structural
changes of the NBD upon Mg2+-ATP binding are transmitted to
the TMD through a relay of van der Waals interactions involving
the side chains around IH2* (Fig. 5c). A cryo-EM study of human
P-gp also suggested that the Q-loop coordinates Mg2+ with the γ-
phosphate of ATP and forms part of the interface between the
NBD and TMD, interacting with the coupling helices15.
We also identiﬁed a pairing between Glu620α6 and Arg644*α7
or Glu620*α6 and Arg644α7 at the bottom of the NBDs, which
allows the formation of a salt bridge and stabilizes NBD dimer
formation (Fig. 5d). Interestingly, the salt bridges are at the NBD
dimer interface near Glu610Walker B and His643H-loop. The
pairing motif, which we term RE-latch, is conserved among the B-
subfamily ABC transporters (Supplementary Fig. 3), but not in



























































Fig. 2 Structural changes forming a substrate pathway from the inner side to the extracellular side. Rearrangement of side chains, primarily in TM1, TM6,
TM1*, and TM6*, between inward- (a) and outward-facing (b) conformations of QTA CmABCB1. (Upper panels) Top views of the extracellular gate,
showing transition of residues lining TM1, TM6, TM1*, and TM6*. (Lower panels) Lateral views of both structures. For clarity, several TM helices (TM1,
TM2, TM3, and TM6) are omitted. One subunit is colored in orange, and the other is shown in gray. The inner chamber in the inward-facing conformation
is shown as a green mesh (a). In b, bound Mg2+•AMP-PNP molecules at NBDs are shown as spheres. Horizontal black and gray bars represent the
expected positions of the hydrophilic and hydrophobic surfaces of the lipid membrane, respectively
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demonstrated by mutagenesis experiments showing that Ala
substitution of Glu620 or Arg644 decreased the substrate
transport and ATPase activities of CmABCB1 (Supplementary
Fig. 5a–c), as well as the ATPase activity of human P-gp
(Supplementary Fig. 5d,e). It remains possible, however, that the
mutations indirectly affected these activities by altering the
structures around the catalytic residues, Glu610Walker B or
His643H-motif, which are located near Glu620α6 or Arg644α7,
respectively (Fig. 5d). The alignment reveals that the residues
participating in the Mg2+-nucleotide−NBD and NBD−TMD
interactions are conserved in transporters whose structures have
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Discussion
The conformational change between the apo inward-facing and
Mg2+-nucleotide-bound outward-facing X-ray structures pro-
vides insight into the mechanism of multidrug transport. We
propose that the active transport of diverse substrates by P-
glycoprotein is mediated by alternative contraction and dilation
of the inner chamber (Fig. 6). These changes are promoted by the
dimerization and dissociation cycles of the two NBDs, coupled
with Mg2+-ATP binding and hydrolysis. From the inward-facing
to the outward-facing conformation, Mg2+-ATP binding to the
NBDs causes a conformational change in the TMDs mediated by
NBD−TMD interactions, aided by a relay of van der Waals
interactions among the side chains of residues in the helical
subdomain of the NBD, coupling helices, and TM helices upon
Q-loop−Mg2+-ATP interaction. Consequently, the volume of the
chamber is signiﬁcantly decreased by TM3−TM3*, and both the
TM3−TM6* and TM3*−TM6 interactions are manipulated by
the chamber contraction regulator (Gln398 and Ala240) and TM
joints (TM1−TM3 and TM3−TM6). The conformational change
simultaneously breaks the TM1−TM6 interaction, consisting of
the van der Waals contacts and hydrogen-bonding network in the
cluster of aromatic hydrophobic side-chains9, and opens the
extracellular gate via twisting of TM6 and TM6*. It is possible
that the opening of the extracellular gate liberates the substrate to
the extracellular space, and that the RE-latch (Glu620 and
Arg644) stabilizes the outward-facing conformation until the
substrate is expelled. Because the potential energy generated by
NBD dimerization upon ATP binding is stored in the structural
strain of the TMDs, especially TM3, TM3*, TM6, and TM6*,
when ATP is hydrolyzed, the potential energy must be trans-
formed into force to return from the outward-facing to the
inward-facing conformation. The narrowness of the opening of
the extracellular gate in our structure of the outward-facing state
suggests that substrates are transported to the extracellular space
rather than into the lipid bilayer (Supplementary Fig. 2a).
In general, the outward-facing high-resolution crystal structure
of Mg2+-nucleotide-bound homodimeric CmABCB1 is similar to
the cryo-EM structure of monomeric human P-gp15, suggesting
that common substrate recognition and structural change
mechanisms are involved in multidrug export. Despite the
molecular constitution of the dimer or monomer, both substrate
binding sites have a cluster of hydrophobic aromatic residues that
can offer adaptive plasticity and gating through the extracellular
space. Residues able to form H-bonds, corresponding to Gln147
and Thr381 of CmABCB1, are found in the TMD1 of mammalian
P-gp (Supplementary Fig. 3), implying similar stabilization of the
inward-facing conformations. However, the residues participating
in chamber regulation differ between human P-gp and
CmABCB1. Asymmetric P-gp has a substrate binding site regu-
lated by additional inhibitors and modulators23,24, and sometimes
two NBDs exhibit asymmetric behavior in ATP binding and
hydrolysis10,14,25. The structure of chimeric P-gp bound to
zosuquidar26 also revealed some differences from the apo inward-
facing CmABCB1 structure: both TM4 and TM10 structures
must be structurally ﬂexible, but the observed conformational
change triggered by NBD dimerization is different. These phe-
nomena could be due to an intrinsic difference in the molecular
architecture or the effect of antibody binding to chimeric P-gp.
In the case of P-gp, inward-facing conformations are more
stable than outward-facing conformations with bound ATP,
whereas in the bacterial homologs MsbA and Sav1866, the two
states have similar conformational stability13,14. The difference in
the conformational stability of P-gp may permit the existence of
short-lived outward-facing conformations during ATP hydro-
lysis, followed by rapid reversal to the inward-facing state after
hydrolysis14. Until now, however, the structural and thermo-
dynamic factors underlying the differences in the stability of
states between the P-gp and bacterial homologs, despite simila-
rities in their molecular structures, have remained enigmatic.
Our study provides some answers. First, our structures of two
states of the same P-gp reveal profound structural differences in
the outward-facing states of CmABCB1 and bacterial homologs
that function as ﬂoppases. Secondly, key structural determinants
that are conserved in mammalian P-gps underpin the mechanism
by which ATP binding and hydrolysis initiate local structural
changes that are propagated throughout the entire molecule, from
NBD to TMD. The instability of the outward-facing conforma-
tion seems to arise from accumulated elastic strain in the coiled
spring-like transmembrane helices (Fig. 3c, d), which is caused by
NBD dimerization upon ATP binding. Release of this strain
drives a rapid reversal to the inward-facing state upon hydrolysis.
Methods
Chemicals. Substrates for CmABCB1 were purchased from Wako, except for
tetraphenylphosphonium bromide (Tokyo Chemical Industry), monensin (Alexys),
and calcein AM (Nacalai).
Construction of CmABCB1 and human P-gp mutants. CmABCB1 and human P-
gp mutants were made by PCR site-directed mutagenesis. Five CmABCB1 mutants,
E610A, Y233A, K237A, A240F, and Q398A, were constructed by QuikChange site-
directed mutagenesis kit (Stratagene), and the other ﬁve mutants, Q147A/T381A,
G132V, A246V, E620A, and R644A, were by QuikChange Multi system (Strata-
gene) using corresponding primers (Supplementary Table 2) and pABC3 harboring
CmABCB1 gene with a C-terminal FLAG and His6 afﬁnity tags9. Human P-gp
mutants were made by PrimeSTAR mutagenesis (Takara Bio) and In-Fusion HD
cloning (Clontech) using corresponding primers (Supplementary Table 2) and the
pcDNA3.1 vector harboring human P-gp gene with FLAG tag27, which was
modiﬁed by the insertion of the TEV protease cleavage site and the His10 afﬁnity
tag at 5′ region of FLAG tag with oligo nucleotides (Supplementary Table 2) and
the restriction enzyme (Not I). All mutants were conﬁrmed by DNA sequencing.
Expression of CmABCB1. To obtain wild-type and mutants of CmABCB1, the
proteins were expressed in Saccharomyces cerevisiae AD1-8u− cells28. The cells
Fig. 3 Large change in the chamber volume. a, b The inside anterior views of inward- (a) and outward-facing (b) conformations of QTA CmABCB1. For
clarity, TM4, TM5, TM4*, and TM5* shown in Fig. 1a, c are omitted here. Residues forming close inter-subunit contacts on the cytosolic side in the
outward-facing conformation are shown as spheres. The inner chamber in the inward-facing conformation is shown as a green mesh (a). One subunit is
shown in color, and the other is shown in gray. Horizontal black and gray bars represent the expected positions of the hydrophilic and hydrophobic surfaces
of the lipid membrane, respectively. In b, bound Mg2+•AMP-PNP molecules at NBDs are shown as spheres. c, d Close-up of TM6* and TM3 in inward- (a)
and outward-facing (b) conformations viewed parallel to the membrane. Intra-helical interactions within the main chains of TM6 are shown as dashed
lines. In c, the internal large cavity facing the intracellular side in the inward-facing conformation is outlined in green. In d, TM3 and the side chains of
residues interacting with Gln398 are shown as ribbon and sticks, respectively. Polar and van der Waals interactions are shown as black and orange dashed
lines, respectively. Non-α-helical hydrogen bonds in TM6 are indicated by red arrowheads. The stretching directions of TM6 from the inward- to outward-
facing conformations are shown as thick black arrows in the schematic. e Bar graph, overlaid with the actual data points, shows IC50 for growth inhibition in
a rhodamine 6G susceptibility assay using S. cerevisiae AD1-8u− cells. Error bars indicate standard deviation (n= 3). Cells expressing the ATPase-deﬁcient
mutant E610A served as controls. Inset shows the amounts of mutant and WT CmABCB1 expressed in AD1-8u− cells, as determined by western blotting.
Uncropped images of the blots are shown in Supplementary Fig. 6
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CmABCB1    127 ASILEGATLPA  137      237 KLGAVLFNLAQCVVGI  252      384 FSAILGFMGVGQAAQVWPD  402
HsPgp_N     57 AAIIHGAGLPL   67      189 KIGMFFQSMATFFTGF  204      336 FSVLIGAFSVGQASPSIEA  354
HsPgp_C    717 CAIINGGLQPA  727      832 RLAVITQNIANLGTGI  847      979 SAVVFGAMAVGQVSSFAPD  997
MmPgp_N     56 AAIIHGVALPL   66      185 KIGMFFQAMATFFGGF  200      332 FSVLIGAFSVGQASPNIEA  350
MmPgp_C    713 CAIINGGLQPA  723      828 RLAVIFQNIANLGTGI  843      975 SAIVFGAMAVGQVSSFAPD  993
CePgp_N     83 VAVITGAGLPL   93      213 KIGMAFQYLSQFITGF  228      360 SSVMMGSMALGLAGPQLAV  378
CePgp_C    760 TATIGGFIYPT  770      873 RFSTVITTLVSMVAGI  888     1022 YAITISTSTLGFATSYFPE 1040
Sav1866     22 VGIIKFGIPML   32      138 GLMNIWLDCITIIIAL  153      285 GYLELLFGPLRRLVASFTT  303















































Fig. 4 TM joints characterizing the outward-facing structure of P-gp. a, b Inter-helical interactions of TM1−TM3 and TM3−TM6 of inward- (a, left) and
outward-facing (a, right) conformations of QTA CmABCB1, and comparison with outward-facing structure of Sav1866 (b). Residues serving as TM joints in
CmABCB1 and corresponding residues in Sav1866 are shown as spheres. Only the TMD of one subunit is shown for simplicity. c–e Arrangement of TM
joints of outward-facing QTA CmABCB1 (c) and human P-gp (d) viewed from the extracellular side and comparison with Sav1866 (e). TM1 (TM1* or TM7),
TM3 (TM3* or TM9), and TM6 (TM6* or TM12) are shown as cylinders. Residues serving as TM joints in CmABCB1 and the corresponding residues in
human P-gp and Sav1866 are shown as spheres. f Local sequence alignment of the TM joints consisting of TM1, TM3, and TM6. Conserved Gly and other
residues with small side chains, such as Ala, and Ser, are highlighted. g Bar graph, overlaid with the actual data points, shows IC50 for growth inhibition in
rhodamine 6G susceptibility assay using S. cerevisiae AD1-8u− cells. Error bars indicate standard deviation (n= 3). Cells expressing the ATPase-deﬁcient
mutant E610A served as controls. Inset shows the amounts of mutant and WT CmABCB1 expressed in AD1-8u− cells, as determined and analyzed by
western blotting. Uncropped images of the blots are shown in Supplementary Fig. 6
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were precultured in 20 ml of extract-peptone-dextrose (YPD) medium for over-
night at 30 °C with shaking at 240 rpm (BioShaker BR-23FP, TAITEC). The pre-
cultured cells were inoculated in 400 ml of YPD medium to an OD600 of 0.5, and
were cultured at 30 °C up to an OD600 of 5. The cells were then diluted in 8 L of
YPD medium to an OD600 of 0.1, and were grown in eight 2.5-L ﬂasks (Thomson)
at 25 °C with shaking at 240 rpm using an Innova 4330 incubator shaker (New
Brunswick Scientiﬁc). After 24 h, cells were harvested by centrifugation (3000 × g,
15 min) and stored at −80 °C until use.
Puriﬁcation of CmABCB1. The yeast cells were thawed on ice and disrupted using
an EmulsiFlex-C3 (Avestin) at 25,000 psi in a buffer containing 20 mM Tris-HCl
(pH 7.0) and 150 mM NaCl. The homogenate was clariﬁed by centrifugation at
1500 × g for 15 min to remove the unbroken cells and nuclei, and then crude
membranes were collected by ultracentrifugation (100,000 × g, 1 h). The mem-
branes were mechanically homogenized and subsequently solubilized for 1 h in a
binding buffer (20 mM Tris-HCl (pH 7.0), 300 mM NaCl, 20 mM imidazole)
containing 1% (w/v) polyoxyethylene(9)dodecyl ether (C12E9) (Wako). Insoluble
material was removed by ultracentrifugation (100,000 × g, 1 h) and immobilized
metal−ion afﬁnity chromatography (IMAC) resin (Bio-Rad) was added to the
supernatant. After a 3-h incubation, the bound protein was eluted with binding
buffer containing 300 mM imidazole. After cleaving the ﬂexible N-terminal region
(1−92) by trypsin treatment9, the IMAC-puriﬁed CmABCB1 were further puriﬁed
by gel ﬁltration using a Superdex200 column (GE Healthcare) equilibrated in a
buffer composed of 20 mM Tris-HCl (pH 7.0), 150 mM NaCl, and 0.2% (w/v)
n-decyl-β-D-maltopyranoside (βDM) (Anatrace). Peak fractions were pooled and
concentrated to 10 mgml−1 for crystallization experiments. In the preparation
used for ATPase activity assays, membranes (5 mgml−1 protein) were solubilized
using 1% (w/v) n-dodecyl-β-D-maltopyranoside (βDDM) (Anatrace) instead of
C12E9 and puriﬁed in 0.05% (w/v) βDDM without the trypsin treatment.
Crystallization. Crystallization was carried out by the sitting-drop vapor diffusion
method at 20 °C. For crystallization of the outward-open form, the QTA mutant
was preincubated for 1 h with 10 mM AMP-PNP and 20mM MgCl2. Crystals of


















































































Fig. 5 Coupling between NBD−TMD and NBD−NBD* in the outward-facing conformation of QTA CmABCB1. a NBD bound to Mg2+•AMP-PNP in a
subunit of QTA CmABCB1, viewed parallel to the membrane. The NBD and TM2−IH1−TM3 of one subunit are shown in white, except for Q-loop-α3,
shown in magenta; TM4*−IH2*−TM5* and α6* of the other subunit are shown in orange. The key residues for coupling between NBD−TMD and NBD
−NBD* are shown as magenta sticks. b Octahedral coordination of Mg2+. Light blue and blue meshes represent the 2Fo−Fc map contoured at 2.7 and
4.5 sigma, respectively. Polar interactions are shown as dashed lines. c Superposition of the NBDs in the outward- (gray) and inward-facing (white)
conformations, based on the RecA-like subdomain. The direction of movement of α3 and Gln529 between the inward- and outward-facing conformations
are shown as arrows. Residues contributing to the coupling of movement between the NBD and TMD are shown as sticks. d Interaction between NBDs
stabilized by RE-latch. The salt bridges in RE-latch are shown as red dashed lines, and the boundary between the two NBDs is shown as gray dashed lines
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volume of reservoir solution containing 19−21% PEG 2000 MME, 50 mM potas-
sium nitrate (pH 7.4), and 50 mM magnesium nitrate (pH 4.1). Crystals were
cryoprotected by increasing the PEG 2000 MME concentration to 30%, followed by
increasing the 1,4-butanediol concentration to 5%. Cryoprotected crystals were
ﬂash-frozen and stored in liquid nitrogen. Mercury-derivative crystals of outward-
open QTA were prepared by soaking the native crystals in reservoir solution
supplemented with 1 mM mercury chloride for 1 day, followed by back-soaking.
Crystals of inward-open QTA were grown by mixing protein (10 mgml−1) with an
equal volume of reservoir solution containing 14% PEG 2000 MME and 100 mM
magnesium nitrate (pH 4.1). Cryoprotection was performed as described above.
Data collection and structure determination. X-ray diffraction data sets of
outward-open, Hg derivative, and inward-open QTA crystals were collected using
an MX225HE detector (for outward-open QTA: camera length, 200 mm; scan step,
0.5°; exposure time, 0.5 s; scan angle, 90˚; attenuator, Al 600 µm; for Hg derivative:
camera length, 260 mm; scan step, 1.0˚; exposure time, 1.0 s; scan angle, 180˚;
attenuator, Al 400 µm) or a PILATUS 6M detector (for inward-open QTA: camera
length, 600 mm; scan step, 0.5˚; exposure time, 0.5 s; scan angle, 180˚; attenuator,
Al 1140 µm), at beamline BL41XU of SPring-8 (Hyogo, Japan). Diffraction data for
inward-open and outward-open QTA were processed using XDS29, and data for
the Hg derivative were processed using HKL2000 30. The initial phases for the
outward-open and inward-open structures of QTA were solved by single-
wavelength anomalous diffraction using a mercury-derivative and molecular
replacement, respectively. Each ﬁnal model was obtained by an iterative process of
manual model-building with COOT31 and reﬁnement with REFMAC532 and
PHENIX33 against X-ray diffraction data. Details of data collection and reﬁnement
statistics are summarized in Table 1. Molecular graphics were rendered in
PyMOL34.
Drug susceptibility assay in yeast cells. Transport activity of CmABCB1 was
assayed by assessing the drug susceptibility of S. cerevisiae AD1-8u− cells
expressing wild-type or mutant CmABCB19. The cells were precultured in YPD
medium at 30 °C for 16 h. The precultured cells were inoculated in YPD medium to
an OD600 of 0.5. The cells were then cultured at 30 °C up to an OD600 of 2−3. The
cultured cells were diluted in YPD medium to an OD600 of 0.2, and 50 µl of each
cell suspension was inoculated into 450 µl YPD medium containing a drug at the
indicated concentration in a 96-well V-shaped MasterBlock (Greiner Bio One).
After culture at 30 °C for 13−14 h in YPD medium containing rhodamine 6G,
etoposide, itraconazole, tetraphenylphosphonium, monensin, or ﬂuconazole,
optical densities of the cell suspensions were measured at 600 nm. The assay was
performed using 4−8 clones, and the averages and standard deviations of measured
values were calculated. Expression levels of mutant proteins were evaluated by
western blotting analysis with anti-His (1014992, Qiagen, 1:5000) or anti-GAPDH
antibody (MA5-15738, Invitrogen, 1:5000). Cells expressing ATPase-deﬁcient
mutant E610A were used as negative controls.
Expression and puriﬁcation of human P-gp. WT and mutant P-gps were tran-
siently expressed by PEI-mediated transfection35 in suspension culture-adapted
HEK293 cells (FreeStyle 293-F cells; Thermo Fisher). Cells were transfected with a
mixture of PEI-MAX (Mw 40,000; Polysciences) and plasmids at ﬁnal con-
centrations of 4 μg ml−1 and 1 μg ml−1, respectively. For puriﬁcation, P-gp-
expressing cells were solubilized with 1% C12E8 in solubilization buffer (50 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-Na (pH 7.2), 150 mM
NaCl, 50 mM KCl, 10% glycerol, and 1 mM 2-mercaptoethanol) supplemented
with protease inhibitors (Complete EDTA-free; Roche Applied Science). After
insoluble materials were removed by centrifugation (45,000 × g, 30 min), ANTI-
FLAG M2 Afﬁnity Gel (A2220, Sigma-Aldrich) was added, and the sample was
incubated for 2 h. Proteins were eluted in solubilization buffer containing 0.05%
C12E8 and 0.15 mgml−1 each of FLAG peptide and 3× FLAG peptide, and then
concentrated to 0.5−2 mgml−1 using Amicon Ultra 0.5 ml ﬁlters (100,000, Merck
Millipore).
ATPase measurements. ATPase activity of puriﬁed CmABCB1 in βDDM micelles
was measured in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.05% βDDM, and
10 mM MgCl2 with or without ATP, containing the indicated compounds. The
ATPase activity of CmABCB1 reconstituted in proteoliposomes was measured
under the same conditions, except that βDDM was omitted. To prepare liposomes,
egg L-α-phosphatidylcholine lipids (Avanti) dissolved in chloroform were dried and
hydrated with buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM
MgCl2, and 2 mM dithiothreitol. The hydrated lipid suspension was subjected to
ﬁve freeze-thaw cycles and sonicated in a bath sonicator until the suspension
clariﬁed. To reconstitute CmABCB1 into liposomes, 1.0 mg ml−1 puriﬁed
CmABCB1 in buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and
0.05% βDDM was mixed with an equal volume of 10 mgml−1 lipid suspension,
diluted to 50 μg ml−1 protein concentration in buffer containing 20 mM Tris-HCl
(pH 7.5) and 150 mM NaCl, and then incubated at 23 °C for 20 min. The ATP
hydrolysis reaction of CmABCB1 was performed at 37 °C, and the initial hydrolysis
rate was measured by detecting inorganic phosphate released from ATP using a
colorimetric method9. The ATPase activities of puriﬁed CmABCB1 determined in
detergent micelles were similar to those in liposomes (Supplementary Fig. 1d,e) and
those of puriﬁed human P-gp determined in liposomes36.
To analyze the ATPase activity of human P-gp, puriﬁed proteins were
reconstituted in egg lecithin liposomes, and ATPase reactions were carried at 37 °C
for 30 min in reaction buffer (40 mM Tris-Cl (pH 7.4), 100 mM NaCl, 0.1 mM
ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA), 2 mM
dithiothreitol, 3 mM MgCl2, and 3 mM ATP). Reactions were stopped by the
addition of EDTA, and released adenosine diphosphate (ADP) was measured by
high performance liquid chromatography (HPLC)37.
Determination of kinetic parameters for the ATPase reaction. Three different
analyses were performed using the following equations9. When the ATPase assay




































Fig. 6 Proposed model for transport mechanism of CmABCB1. Schematic drawing of conformational change between the inward- (left) and the outward-
facing (right) CmABCB1. An expected intermediate state is depicted in the center panel. The characteristic devices indispensable for the mechanics of
transport are represented
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determined using the Michaelis−Menten Eq. (1):
v ¼ kbasal e½  s½ 
KATPm þ s½ 
: ð1Þ
The ATPase assay was performed in the presence of various concentrations of
substrates (rhodamine 6G or verapamil) and 5 mM ATP. Kinetic parameters were
determined using Eq. (2) for WT or RE-latch mutants of CmABCB1 or human P-
gp, and using Eq. (3) for G132V, A240F, A246V, or Q398A mutants of CmABCB1:
v ¼ e½  kbasal þ
ksub  kbasalð Þ s½ 
KDrugm þ s½ 
 !
1 s½ 
KDrugi þ s½ 
 !
; ð2Þ








Here, v is the initial ATP hydrolysis rate; [e] is the concentration of CmABCB1
or human P-gp; [s] is the concentration of ATP or substrates; kbasal and ksub are the
catalytic rate constants of ATPase activity in the absence and presence of substrate,
respectively; KmATP is the Michaelis constant for ATP, KmDrug is the apparent
Michaelis constant for substrate activation, and KiDrug is the apparent inhibition
constant for substrate inhibition. Fitting was carried out using GRAFIT (Erithacus
Software) or KaleidaGraph (Synergy Software).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corre-
sponding author upon reasonable request. Atomic coordinates and structural
factors of the QTA CmABCB1 in the AMP-PNP-Mg2+-bound outward-facing
state and in the inward-facing apo state have been deposited in the Protein Data
Bank under accession codes 6A6M and 6A6N, respectively.
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